{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-056810","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.597571+00:00","generated_at":"2026-06-28T08:17:00.955865+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biodesix Q3 lung diagnostic revenue up 51% YoY; launches 72-hour NGS test","bullets":["Total revenue $6.5M; lung diagnostic revenue $4.5M (+51% YoY), services $1.5M (+133%), COVID-19 testing $0.5M (-91%).","Gross margin 58% (up from 40% in Q2 2021); operating expenses $16.9M (+46%).","Net loss $11.5M (+30%); includes $3.1M non-cash PPP loan forgiveness gain.","Cash and cash equivalents $47.9M as of Sept 30, 2021.","Launched 72-hour liquid NGS test ahead of schedule; broad US launch targeted for Q1 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-056810","json":"https://secwatch.observer/filing/0001564590-21-056810.json","markdown":"https://secwatch.observer/filing/0001564590-21-056810.md","text":"https://secwatch.observer/filing/0001564590-21-056810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/0001564590-21-056810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000156459021056810/bdsx-8k_20211115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:17:00.955865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}